-
Article
Efficacy of Biologics in Patients with Allergic Bronchopulmonary Aspergillosis: A Systematic Review and Meta-Analysis
Treatment of allergic bronchopulmonary aspergillosis (ABPA) is challenging. Biological therapies have been reported as adjunctive treatments for ABPA, primarily in case series or case reports. This study aimed...
-
Article
Open AccessAirway and Systemic Immunoglobulin Profiling and Immune Response in Adult Asthma
Immunoglobulins play a vital role in host immune response and in the pathogenesis of conditions like asthma. Therapeutic agents such as monoclonal antibodies target specific elements of the asthmatic inflammat...
-
Article
Open AccessThe cost-effectiveness of as-needed budesonide-formoterol versus low-dose inhaled corticosteroid maintenance therapy in patients with mild asthma in Canada
The Global Initiative for Asthma recommends the use of as-needed low-dose inhaled corticosteroid (ICS)-formoterol as a preferred controller therapy for patients with mild asthma. These recommendations were bas...
-
Article
Open AccessSafety of As-Needed Budesonide-Formoterol in Mild Asthma: Data from the Two Phase III SYGMA Studies
Budesonide-formoterol taken as needed is an emerging treatment for mild asthma.
-
Article
Open AccessUse of a vibrating mesh nebulizer for allergen challenge
Allergen inhalation tests are a valuable research tool. The allergen dose producing an early asthmatic response (EAR) can be predicted from methacholine responsiveness and allergen skin test endpoint (STE). Th...
-
Article
Open AccessInterleukin-25 and eosinophils progenitor cell mobilization in allergic asthma
Eosinophil-lineage committed progenitor cells (EoP) migrate from the bone marrow and differentiate locally to provide an ongoing source of mature eosinophils in asthmatic inflammatory responses in the airways....
-
Article
Open AccessEfficacy of budesonide/formoterol maintenance and reliever therapy compared with higher-dose budesonide as step-up from low-dose inhaled corticosteroid treatment
Asthma management may involve a step up in treatment when symptoms are not well controlled. We examined whether budesonide/formoterol maintenance and reliever therapy (MRT) is as effective as higher, fixed-dos...
-
Article
Open AccessThe SYGMA programme of phase 3 trials to evaluate the efficacy and safety of budesonide/formoterol given ‘as needed’ in mild asthma: study protocols for two randomised controlled trials
In many patients with mild asthma, the low frequency of symptoms and the episodic nature of exacerbations make adherence to regular maintenance treatment difficult. This often leads to over-reliance on short-a...
-
Chapter
Anti-IgE and Biologic Approaches for the Treatment of Asthma
Current asthma treatments are effective for the majority of patients with mild-to-moderate disease. However, in those with more severe refractory asthma, agents other than inhaled corticosteroids and beta-agon...
-
Article
Open AccessAllerGen’s 8th research conference
-
Article
Open AccessTherapeutic interventions in severe asthma
The present paper addresses severe asthma which is limited to 5-10% of the overall population of asthmatics. However, it accounts for 50% or more of socials costs of the disease, as it is responsible for hospi...
-
Article
Open AccessIntegrated safety and efficacy analysis of once-daily fluticasone furoate for the treatment of asthma
Fluticasone furoate is a once-daily inhaled corticosteroid. This report provides an overview of safety and efficacy data that support the use of once-daily fluticasone furoate 100 μg or 200 μg in adult and ado...
-
Article
Open AccessProceedings of the Canadian society of allergy and clinical immunology annual scientific meeting 2015
A1 Role of fibrocytes in allergic rhinitis
-
Article
Open AccessDose-finding evaluation of once-daily treatment with olodaterol, a novel long-acting β2-agonist, in patients with asthma: results of a parallel-group study and a crossover study
Olodaterol is a novel, inhaled long-acting β2-agonist (LABA) with >24-h duration of action investigated in asthma and chronic obstructive pulmonary disease.
-
Article
Open AccessBlood biomarkers of the late phase asthmatic response using RNA-Seq
-
Article
Open AccessEfficacy and safety of once-daily fluticasone furoate 50 mcg in adults with persistent asthma: a 12-week randomized trial
Fluticasone furoate (FF) is a novel, once-daily inhaled corticosteroid (ICS) that has been shown to improve lung function vs. placebo in asthma patients. This study evaluated the efficacy and safety of FF 50 m...
-
Article
Open AccessTh17/Treg ratio derived using DNA methylation analysis is associated with the late phase asthmatic response
The imbalance between Th17 and Treg cells has been studied in various diseases including allergic asthma but their roles have not been fully understood in the development of the late phase asthmatic response.
-
Article
Open AccessComparison of vilanterol, a novel long-acting beta2 agonist, with placebo and a salmeterol reference arm in asthma uncontrolled by inhaled corticosteroids
Current maintenance therapies for asthma require twice-daily dosing. Vilanterol (VI) is a novel long-acting beta2 agonist, under development in combination with fluticasone furoate, a new inhaled corticosteroid (...
-
Article
Open AccessTh17/Treg ratio derived using DNA methylation analysis discriminates allergen-induced early from dual asthmatic responses
-
Article
The pharmacological modulation of allergen-induced asthma
Aeroallergens are the most common triggers for the development of asthma. Recent birth cohort studies have identified viral infections occurring against a background of aeroallergen sensitization as a potent r...
